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Summary
Uveal melanoma is the most common primary intraocular malignancy in adults and the eye is the second most 
 common site for primary melanoma after the skin. Early recognition is important in protecting visual acuity, saving the eye 
and preventing metastasis. Signs for early detection of uveal melanoma when it simulates a nevus include thickness >2 mm, 
presence of subretinal fl uid, symptoms, orange pigment, margin of the tumour near the optic disc, acoustic hollowness, 
 surrounding halo, and the absence of drusen. This is essential considering that each millimetre increase in melanoma thick-
ness imparts a 5% increased risk for metastatic disease. Delays or inability to make an accurate and early diagnosis may have 
grave consequences. Methods of diagnosis have substantially improved, although clinical diagnosis remains the standard 
method in the eyes with clear media. In eyes with opaque media ultrasound is the most useful ancillary diagnostic tech-
nique. Newer imaging modalities such as optical coherence tomography and fundus autofl ouroscence facilitate in detection 
of subretinal fl uid and orange pigment. Additional molecular biomarkers and cytological features which can predict the 
clinical behaviour of a small melanocytic lesion have been identifi ed. Although the role of a good clinical evaluation cannot 
be underestimated, it is advisable to assess the various radiological, molecular and cytological features in order to enhance 
the accuracy of early diagnosis and improvement in the patients’ prognosis.
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MEALNOM SREDNJE OČNE OVOJNICE: KLINIČKE OSOBITOSTI I DIJAGNOSTIČKE METODE
Sažetak
Melanom srednje očne ovojnice najčešća je primarna zloćudna bolest oka u osoba odrasle dobi, a oko je drugo po uče-
stalosti najčešće sijelo primarnog melanoma nakon kože. Kasna ili pogrešno postavljena dijagnoza može imati ozbiljne 
 posljedice. Rano otkrivanje melanoma srednje očne ovojnice ključno je u prevenciji gubitka vidne oštrine, spašavanju oka i 
sprečavanju razvoja metastaza. Čimbenici koji omogućuju rano otkrivanje malih melanoma srednje očne ovojnice koji se 
mogu zamijeniti s nevusom su debljina tumora > 2 mm, prisutnost subretinalne tekućine, nazočnost simptoma, narančasti 
pigment, rub tumora u blizini optičkog diska, određene ultrazvučne karakteristike tumora te odsutnost druza. Rano otkri-
vanje tumora je vrlo važno obzirom da povećanje debljine melanoma za 1 mm povećava rizik metastatske bolest za 5%. 
Dijagnostičke metode posljednjih su godina znatno unaprijeđene, no klinička dijagnoza i dalje ostaje standardna metoda 
kod očiju s prozirnim optičkim medijima. Ultrazvuk predstavlja najkorisniju pomoćnu dijagnostičku metodu, osobito u 
slučaju zamućenja optičkih medija oka. Novije dijagnostičke metode poput optičke koherentne tomografi je i autofl ou-
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roscencije fundusa olakšavaju otkrivanje subretinalne tekućine i narančastog pigmenta. Također postoje određeni moleku-
larni biomarkeri i citološke značajke tumorskih stanica koje mogu pomoći u predviđanju kliničkog ponašanja male melano-
citne lezije. Iako je uloga dobre kliničke procjene važna i ne smije se podcijeniti, preporuča se i primjena dodatnih dijagno-
stičkih metoda, te određivanje molekularnih i citoloških značajki tumorskih stanica kako bi se omogućila točna rana 
dijagnoza i time poboljšala prognoza bolesnika.
KLJUČNE RIJEČI: melanom srednje očne ovojnice, patogeneza, kliničke osobitosti i dijagnostičke metode
INTRODUCTION
Melanoma is a malignant tumour arising 
from melanocytes. It may originate from the skin, 
mucous membrane, ocular region including uvea, 
conjunctiva, eyelid, orbit and rarely from an un-
known primary site. Although both cutaneous 
and uveal melanomas share the melanocyte as 
their common origin, their clinical behaviour and 
underlying molecular mechanisms are signifi cant-
ly diff erent (1-3).
The eye is the second most common site for 
primary melanoma after the skin accounting for 5% 
of all melanoma cases (1,4). Uveal melanoma is the 
most frequent site of origin ocular melanomas and 
the most common primary intraocular malignancy 
in adults occurring in all parts of the uvea: choroid 
(90%), ciliary body (7%) and iris (2%) (5). The inci-
dence of uveal melanoma has remained relatively 
constant, between fi ve and six cases per million 
people in the United States and Europe (1,2) and is 
slightly more common among men. The incidence 
of uveal melanoma in Europe was found to vary in 
diff erent countries with higher incidences associat-
ed with higher geographic latitude (2 per million in 
Spain and southern Italy; 4–5 per million in France, 
the Netherlands, Switz erland and Germany; and > 
6 per million in the United Kingdom) (6). Predispo-
sition for uveal melanoma is ethnicity, with a white 
to black incidence ratio of 196:1 (7), age with the 
mean age at initial diagnosis being 60 years (6,7), 
light eye colour, fair skin and the inability to tan. 
Other predisposing factors are cutaneous, iris and 
choroidal nevus, ocular or oculodermal melanocy-
tosis and familial uveal melanoma (2,4) which is 
presumed to be related to somatic or germline 
BAP1 (BRCA1 - breast cancer -associated protein 1) 
mutations (2,8,9).
Molecular pathogenesis
The molecular pathogenesis of uveal mela-
noma diff ers from cutaneous melanoma whilst 
both types appear to activate the mitogen-activat-
ed protein kinase (MAPK) pathway; however via 
diff erent mechanisms. While the majority of cuta-
neous melanomas are associated with activation 
of the MAPK pathway, causing mutations in 
BRAF (approx. 50% of cases) or RAS (10% to 25% 
of cases) or loss of function mutations in NF1 (14% 
of cases) (10,11). Uveal melanoma is characterized 
by point mutations in the G protein α-subunits 
GNAQ and GNA1 with mutations in GNAQ and 
GNA11being in about 80% of patients and are mu-
tually exclusive (8,11,12).
Increased risk of metastasis of uveal melano-
ma has been associated with specifi c genetic al-
terations. Monosomy 3 occurs in approximately 
half of uveal melanomas indicating high risk mel-
anoma and metastasis related death. (3,11-14) 
Harbour and colleagues (9) reported that 84% me-
tastasizing uveal melanomas contained BAP1 mu-
tations. BAP1 is located on chromosome 3 and bi-
allelic inactivation of this gene explains the asso-
ciation between monosomy 3 and metastasis risk. 
A more favourable prognosis is correlated with 
SF3B1 and EIF1AX mutations (8,13,15).
Clinical characteristic and diagnosis
Common symptoms of uveal melanoma in-
clude blurred vision, photopsia (fl ashing lights), 
visual fi eld defects, visible tumour, irritation and 
pain whilst metamorphopsia, fl oaters, redness 
and pressure can also occur. Visual impairment is 
usually caused by tumour involvement of the 
macula or by exudative retinal detachments whilst 
almost 30% of patients are asymptomatic at diag-
nosis (2,3,16-18).
Approximately 2% of all uveal melanomas 
arise in the iris most frequently in the inferior 
quadrant (45%) (1,5). Iris melanomas can induce 
secondary glaucoma, corectopia, ectropion uveae, 
hyphaema, causing pain and blurred vision yet 
rarely metastasize. They tend to have a more be-
nign course than other subsets of uveal melano-
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mas however it is still uncertain whether it is due 
to the fact that they are biologically diff erent or 
simply the result of early detection. The overall 
mortality associated with iris melanomas is less 
than 5% due to early diagnosis, given the visible 
location and the relatively low rate of metastasis. 
Only 5% of small iris tumours will demonstrate 
growth over a 5-year interval enabling follow up 
by serial photographs, measurements and oph-
thalmic examinations (16,18,19).
One of the most diffi  cult areas of the uveal 
tract to visually detect is ciliary body, where 7% of 
uveal melanomas arise (Figure 1) (5). At presenta-
tion these tumours are often large, due to delayed 
diagnosis and they often remain undetected until 
the development of visual disturbance or pain 
(18). Sentinel vessels (very enlarged blood vessels 
feeding the tumour) in the episclera as well as epi-
scleral nodules indicate the presence of a tumour. 
Ciliary body melanoma growth may present with 
rapidly progressive lateral cataract due to pres-
sure or infl ammation and may cause secondary 
glaucoma. The overall mortality from ciliary body 
melanoma is approximately 40% (8,3,17).
Ninety percent of uveal melanoma arise in 
the choroid (5) (Figure 2). There are basically two 
clinical subtypes of choroidal melanoma: diff use 
and nodular. The diff use form is an uncommon 
variant that accounts for 4 to 5 % of posterior mel-
anomas. Nodular choroidal melanomas present as 
a dome or mushroom shaped subretinal mass and 
colour may vary from typically brown pigmented 
to amelanotic (Figure 3) (1,16,18).They may cause 
serious secondary sensory retinal detachment ad-
jacent to the tumour. This detachment can be re-
sponsible for visual loss, even though the tumour 
does not directly involve the submacular choroid. 
The retina overlying the tumour may show degen-
erative changes, occasionally to the point of com-
plete att enuation with the tumour perforation into 
the vitreous. The majority of choroidal melano-
mas are discovered during routine fundoscopic 
examination (2-4,7). Posterior uveal melanomas 
are generally graded based on tumour size (Table 
1) (2,17). It has been established that the risk of 
metastasis increases 5% with each 1 mm increase 
in tumour thickness as measured by ultrasonogra-
phy (USG) (20,21). Furthermore other grading 
systems include classifi cation on the basis of clini-
cal, pathologic and genetic factors (2-4,16).
The diagnosis of uveal melanoma is based 
primarily on clinical examination by biomicros-
copy, indirect ophthalmoscopy and in some cases 
gonioscopy. Clinical diagnosis is the most accu-
rate means of detecting a choroidal melanoma in 
patients with clear media (Table 2). Ancillary tests 
including colour fundus photography, ultraso-
nography (USG), fundus fl uorescein angiography 
(FFA), indocyanine green angiography (ICGA), 
optical coherence tomography (OCT), fundus au-
tofl uorescence (FAF) and ultrasound biomicros-
copy (UBM). Computed tomography (CT) and 
magnetic resonance imaging (MRI) can also be 
used in order to confi rm diagnosis. Fine-needle 
aspiration biopsy (FNAB), of the tumour can be 
performed when the clinical diagnosis is unclear 
(2-4,8,17,18).
The most useful ancillary diagnostic and 
monitoring tool in uveal melanoma is ultrasonog-
raphy (USG). It is particularly useful in diagnosis 
of melanoma in eyes where the posterior pole can-
Table 1.
COLLABORATIVE OCULAR MELANOMA STUDY 
CLASSIFICATION OF CHOROIDAL MELANOMA ACCORDING 
TO SIZE 
Classifi cation Thickness (mm) Largest basal diameter (mm)
Small 1.0 to 2.5 5.0 to 16.0





CLINICAL CHARACTERISTICS AND LOCALISATION 
OF UVEAL MELANOMA 
Localisation Frequency Signs and symptoms
Iris 2%
Well circumscribed, pigmented 
masses, corectopia, darkening 
of one iris, unilateral glaucoma, 
blurred vision, pain, loss of corneal 
clarity, hyphaema
Ciliary body 7%
Invasion into the base of iris, 
sentinel vessels, unilateral 
glaucoma, cataract, visual 
disturbances, pain, asymmetric 
astigmatism
Choroid 90%
Solid tumour beneath the retina, 
retinal detachment, vitreous 
haemorrhage, decrease of visual 
acuity, visual fi eld defects, pain
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not be seen directly and should be done routinely 
in all eyes with opaque media (2-4). The A scan is 
accurate in helping to estimate the height of the 
tumour which aids in distinguishing thin melano-
mas from nevi and in assessing its growth over 
time. B-scan USG is useful for characterising the 
tumour and for obtaining tumour dimensions. 
Typical fi ndings in larger melanomas include cho-
roidal excavation and orbital shadowing with the 
tumour showing low to medium internal echo-
genicity.USG is also useful in the evaluation of ex-
traocular extension; areas of hyporefl ectivity com-
pared to normal orbital tissue are considered as 
orbital extensions of the tumour (22,23).
High-resolution ultrasound biomicroscopy 
(UBM) allows excellent visualization of iris and 
ciliary body tumours, which are generally diffi  cult 
to evaluate during clinical examination.UBM iden-
tifi es hyporefl ective plaques on the tumour surface, 
tumour-specifi c vasculature, internal refl ectivity 
and if present, extraocular extension (2,24).
Optical coherence tomography (OCT) is par-
ticularly useful in the diagnosis of small choroidal 
melanomas less than 3 mm in thickness which can 
be misdiagnosed during routine examination. It is 
useful in diff erentiating choroidal nevus from 
small choroidal melanoma and the detection of 
the presence of subretinal fl uid, which is consid-
ered one of the high-risk features predicting trans-
formation into melanoma. However it has limited 
use in tumours larger than 3 mm (2,16,24,25).
Anterior segment OCT (AS-OCT) is a newer 
technique used in the imaging of iris and ciliary 
body melanoma, however is not successful as 
USG owing to its lack of ability to penetrate deep-
er tissues (24). In the absence of AS-OCT, substitu-
tutional diagnostic methods which allows the vi-
sualisation of the tumour may be transillumina-
tion, gonioscopy and biomicroscopy (22).
Flourescein angiography (FFA) is another 
valuable technique in diagnosis of melanoma. A 
frequent fi nding is double-circulation, the patt ern 
that refers to the fi lling of the retinal vessels over-
lying the tumour, superimposed on dilated ves-
sels within the tumour itself. The retinal pigment 
epithelium overlaying choroidal melanomas is 
frequently altered, and focal defects are seen as hot 
spots as they leak fl uorescein. Other typical fl uo-
rescein patt erns include areas of capillary nonper-
fusion and blockage of larger retinal vessels. 
(2,16,18,26). FFA is also used in the detection and 
follow-up of complications arising after brachy-
therapy such as radiation retinopathy and radia-
tion maculopathy (2,16).
Indocyanine green (ICG) angiography is an 
alternative technique for imaging choroidal vas-
culature which shows details of choroidal circula-
tion more eff ectively than fl uorescein. It can be 
combined with scanning laser conofocal micros-
copy to study the vasculature at a particular level 
(16,18,26).
On fundus autofl uorescence imaging (FAF), 
pigmented tumours exhibit moderate hypoauto-
fl uorescence, whilst nonpigmented (amelanotic) 
tumours show moderate hyperautofl uorescence. 
These regions of hyperautofl uorescence are visi-
ble owing to the presence of orange pigment, dru-
sen and subretinal fl uid overlying the tumour. 
FAF may also reveal hypoautofl uorescent retinal 
pigment epithelium defects, such as hyperplasia, 
atrophy and fi brous metaplasia or hyperautofl uo-
rescent drusen, which may suggest chronic stable 
nevus (27).
Computed tomography (CT) and magnetic 
resonance imaging (MRI) can be utilized when 
tumours cannot be visualised by clinical examina-
tion in patients with opaque media (cataract, vit-
reous haemorrhage or retinal detachment) and if a 
diff erential diagnosis is still not possible after 
USG. These imaging methods also have an impor-
tant role in the evaluation of extraocular extension 
(2,18,22).
Fine-needle aspiration biopsy (FNAB) is a 
technique that may be useful in the diff erential di-
agnosis in selected cases and may be warranted 
for diagnostic dilemmas, particularly if it alters 
subsequent management. Anterior segment tu-
mours can be evaluated by aqueous humour sam-
pling, incisional or excisional biopsy. Transscleral, 
transvitreal or transcameral FNAB, vitrectomy bi-
opsy, incisional or excisional biopsy can be done 
in order to evaluate posterior segment intraocular 
tumours. Needless to say the result obtained with 
FNAB for the sampled area may not be represen-
tative of the entire tumour (3,18,28).
Diff erential diagnosis
A number of lesions can stimulate melano-
ma, especially those with clinically dark appear-
ance. The most common diff erential diagnosis is 
melanocytic nevi which is diffi  cult to distinguish 
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from small melanomas. Metastatic tumours can 
stimulate amelanotic melanomas however they 
tend to be bilateral and multifocal and the patients 
usually have a known primary tumour. Subretinal 
blood can appear as dark rounded lesions simu-
lating melanoma. With time this blood will disap-
pear or be replaced by fi brous scar. Diseases such 
as age-related macular degeneration or disciform 
scars can also be mistaken for melanoma. Retinal 
pigment epithelial proliferation occurs in response 
to many stimuli including ocular trauma, intraoc-
ular infection or infl ammation and retinal detach-
ment. In some cases FNAB has proven useful. Fur-
thermore choroidal hemangioma and choroidal 
osteoma can simulate melanoma. Hemangiomas 
are orange-red in appearance; nearly the same co-
lour as the fundus and usually do not change size 
appreciably. USG shows more internal refl ectivity 
than is typical for melanoma. Choroidal osteomas 
are amelanotic lesions with minimal elevation and 
can be diagnosed by their characteristic USG or 
CT appearance (2-4,17,18).
Risk factors for metastasis
 Even though the lesion is ophthalmoscopi-
cally visible it can be considerably diffi  cult to dif-
ferentiate a nevus from a small choroidal melano-
ma. Shields et al. (29) proposed the mnemonic to 
fi nd small ocular melanoma using helpful hints daily 
namely T-thickness greater than 2 mm, F-subreti-
nal fl uid, S-symptoms, O-presence of orange pig-
ment, M-margin within 3 mm of the optic disc, H-
ultrasound hollowness, H- absence of surround-
ing halo and D- absence of drusen. The further 
management of the melanocitic lesion is impor-
tant due to the prognostic implications and psy-
chological impact of the disease (Table 3). With 
advancement in molecular biology and cytogenet-
ics, several biological and cytological markers 
have been identifi ed which can predict the prog-
nosis of the tumour and aid with decision making 
(29,30).
Clinical risk factors
Tumour size has been a substantial predictor 
of prognosis of the disease. Large tumours are as-
sociated with poor prognosis and higher metastat-
ic rates. Shields et al. reported that each millimetre 
increase of melanoma thickness causes a 5% in-
creased risk for metastatic disease (20). Other clin-
ical features found to be predictive of metastasis 
in their analysis were increasing age, ciliary body 
location, more pigmented tumour and the pres-
ence of subretinal fl uid, intraocular haemorrhage 
or extraocular extension. Additionally, the great-
est basal diameter of the tumour also has an im-
pact on patient prognosis. Diff use melanoma 
which has been defi ned as a tumour with thick-
ness < 20% of the tumour base had a greater risk of 
metastasis and death. A 5 mm increase in basal 
diameter of the tumour increases the risk of me-
tastasis by 5.6 times. Melanocytosis is also a risk 
factor for uveal melanoma development and met-
astatic spread (30).
Histopathological risk factors
Histopathological features are the bases for 
diagnosing ocular melanoma and diff erentiating 
it from a nevus. McLean et al. at the Armed Forces 
Institute of Pathology (AFIP) proposed histopath-
ological classifi cation of uveal melanoma: spindle 
cell nevus, spindle cell malignant melanoma, 
mixed cell melanoma and epithelioid cell mela-
noma (31). According to this classifi cation, spindle 
cell tumours are linked with the best prognosis 
and epithelioid cell tumours with the less favour-
able. Juxtapapillary placed and ciliary body tu-
mours are in most cases epitheloid cell tumours 
and are also more likely to metastasize and prog-
ress (32). A diff use growth patt ern has been shown 
to be related to a higher incidence of extraocular 
extensions and greater metastatic ability (32). 
Presence of mitotic fi gures is connected with ma-
Table 3.
MANAGEMENT GUIDELINES OF MELANOCYTIC LESION 
OF UVEAL TRACT ACCORDING TO THE RISK FACTORS 
(SHIELDS ET AL., 2009.)
Number of 
risk factors Hazard ratio Management
1-2 3 Monitoring every 4-6 months
3-4 5 Refer to an experienced centre for ocular oncology evaluation
5-6 9 Refer to ocular oncology centre for further management
≥ 7 21 Urgent referral to ocular oncology centre
Risk factors: tumour thickness > 2 mm, subretinal fl uid, symptoms, the or-
ange pigment, tumour margin near to the optic disc, ultrasound hollow-
ness, absence of surrounding halo, absence of drusen
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lignancy and is a well-known risk factor for me-
tastasis (32). Increased pigmentation of the tu-
mour is associated with epithelioid cell type with 
necrosis and the presence of macrophages, which 
indicate an increased risk of malignancy (30,32).
Molecular risk factors
It is well known that micro-metastasis of uve-
al melanoma may occur prior to primary treat-
ment and such metastasis can in fact remain unde-
veloped for a prolonged period of time (30,33). 
Identifi cation of high-risk patients is of greater 
importance in treatment planning. Uveal melano-
ma cells disseminate hematogenouslly and thus 
hematological markers may be useful for the de-
tection of distant metastases. The potential mo-
lecular markers for the early detection of dissemi-
nated tumour cells includes increased serum ty-
rosinase m-RNA levels, hepatocyte growth factor 
and its receptor c-Met levels, over expression of 
vascular endothelial growth factor (VEGF) and 
decreased insulin-like growth factor-1 (IGF-1). Re-
gardless of the potential benefi t of serum molecu-
lar markers in determining metastatic disease at a 
subclinical level their use in monitoring is limited 
owing to a wide variety in the normal range of val-
ues within the population (30).
Cytological risk factors
With advancements in treatment of choroidal 
melanoma the importance of obtaining a sample 
for evaluation of prognostic markers is growing. 
In fact FNAB could prove to be a reliable tool for 
genetic testing of uveal melanoma (2,10,14,30).
Chromosomal alterations
The major chromosome alterations character-
istic for uveal melanoma correlated with the clini-
cal high-risk factors for metastasis have been 
found in chromosomes 3, 6, 8, and 11. Monosomy 
of chromosome 3 is associated with a 5-year sur-
vival rate of approximately 50%, whilst disomy of 
chromosome 3 reports a 100% survival rate. Using 
gene expression profi ling, melanomas have been 
categorized into two groups. Class I indicates tu-
mours with two copies of chromosome 3 (disomy 
3) and other benefi cial chromosome changes such 
Figure 1. Ciliary body melanoma
Figure 2. Choroidal melanoma
Figure 3. Amelanotic choroidal melanoma
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as gain in chromosome 6p. Class II includes tu-
mours with only one copy of chromosome 3 
(monosomy 3) and other detrimental chromosome 
changes including gain of chromosome 8p and/or 
isochromosome 8p (30,34).
Gene alterations
Mutations in genes GNAQ and GNA11 have 
been associated with the development of uveal 
melanoma (11,30). Both genes up-regulate the 
MAPK pathway in melanocytes when active si-
multaneously. In fact nearly 83.0% of uveal mela-
nomas have constitutively active mutation in ei-
ther GNAQ or GNA11 (30,35).
CONCLUSION
Uveal melanoma is a rare yet fatal disease 
whose biological behaviour is notably diff erent 
from other forms of melanoma requiring distinct 
treatment strategies. Improvement in local treat-
ment has not provided an increase in survival and 
new treatment options in patients with metastatic 
disease are needed. Even though no standardized 
treatment for metastatic uveal melanoma exists, 
considerable progress has been made to improve 
our understanding of the biology of this type of 
melanoma, leading to novel targeted therapy and 
immunotherapy approaches. Therefore early de-
tection and proper management of malignancy is 
crucial in preventing metastasis and thereby pa-
tient survival.
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